Corsair Pharma

aid: corsair-pharma
name: Corsair Pharma
description: 'Corsair Pharma, Inc. is a privately held clinical-stage biopharmaceutical company developing proprietary prodrugs
  of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Its lead program, the TRX-248 transdermal system,
  is an investigational once-daily patch that delivers an inactive treprostinil prodrug across the skin for conversion to
  active drug in the liver, aiming to combine the efficacy and titration profile of parenteral prostacyclin therapy with non-invasive
  once-daily dosing. The company completed its preclinical program, announced positive Phase 1 results for TRX-248 in June
  2026, closed a $23M Series B led by New Rhein Healthcare Investors, and has entered a strategic collaboration with United
  Therapeutics to advance novel treprostinil prodrugs. Corsair Pharma is a drug developer, not a software vendor: its public
  web presence is a five-page marketing and investor-news site with no developer program, API, SDK, or machine-readable specification
  of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/corsair-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.23'
created: '2026-08-11'
modified: '2026-08-11'
image: https://static.wixstatic.com/media/eb8f76_be22d65dbdb84f7dbd3bae3f30cf754e~mv2.png
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Drug Development
- Clinical Trials
- Pulmonary Arterial Hypertension
- Transdermal Delivery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/corsair-pharma-domain-security.yml
- type: Website
  url: https://www.corsairpharma.com/
- type: Blog
  url: https://www.corsairpharma.com/news
- type: BlogRSS
  url: https://www.corsairpharma.com/blog-feed.xml
- type: PrivacyPolicy
  url: https://www.corsairpharma.com/privacy-policy
- type: TermsOfService
  url: https://www.corsairpharma.com/terms-of-use
x-enrichment:
  date: '2026-08-11'
  status: minimal
  pass: local-v1
  artifacts_added: 2
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Corsair Pharma is a clinical-stage drug developer whose entire web presence is a five-page Wix marketing site (home,
    news, team, privacy-policy, terms-of-use) with no developer, API, docs or partner section; the live host additionally
    answers every path with a SiteGround "Robot Challenge Screen" (HTTP 202), so the page inventory and the absence of any
    /.well-known document were confirmed from Wayback Machine captures instead.
  evidence:
  - url: https://www.corsairpharma.com/
    status: 202
  - url: https://www.corsairpharma.com/openapi.json
    status: 202
  - url: http://web.archive.org/web/2025id_/https://www.corsairpharma.com/developers
    status: 404
  - url: https://web.archive.org/web/20240405094716/https://www.corsairpharma.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/corsairpharma
    status: 404
  - url: https://pypi.org/pypi/corsair-pharma/json
    status: 404
  checked: '2026-08-11'